STOCK TITAN

Certara, Inc. - CERT STOCK NEWS

Welcome to our dedicated page for Certara news (Ticker: CERT), a resource for investors and traders seeking the latest updates and insights on Certara stock.

Overview of Certara, Inc.

Certara, Inc. (symbol: CERT) is a global provider renowned for its biosimulation technology and advanced decision support systems that drive model-informed drug development. Utilizing scientific software and consulting services, Certara empowers biopharmaceutical companies, academic researchers, and regulatory agencies to optimize drug discovery processes and enhance patient care. The company excels in leveraging biosimulation, drug development, and model-informed development techniques to provide robust solutions that transform the way medicines are developed, assessed, and regulated.

Business Focus and Core Offerings

Certara integrates highly specialized simulation software with expert regulatory consulting and technology solutions. Its offerings are designed to streamline various stages of the drug development lifecycle, from early discovery to clinical trial design and regulatory submissions. By bridging complex scientific data and actionable insights, the company assists in reducing the reliance on extensive clinical trials, accelerates regulatory approvals, and enhances patient access to novel therapies.

Advanced Technology and Simulation Capabilities

The company is at the forefront of innovation with its comprehensive suite of software solutions. Certara's offerings include modeling and simulation platforms which incorporate advanced techniques such as quantitative systems pharmacology (QSP) and physiologically-based pharmacokinetics (PBPK). These tools are designed to simulate human physiology and drug interactions, thereby refining dosing strategies and minimizing risk during clinical development phases. The introduction of integrated solutions, such as Certara Cloud, demonstrates the seamless connectivity of different software products, enabling customers to manage licenses, perform detailed analysis, and generate reliable insights within a unified workflow.

Regulatory Science and Consulting Services

Certara's expertise extends into regulatory science and consulting, areas that are critical for navigating the complex frameworks of drug development. By offering detailed regulatory strategies and scientific consulting, the company supports clients in meeting the rigorous requirements of global health authorities. The unique combination of advanced modeling software and regulatory insight helps clients reduce uncertainty and increase the probability of successful regulatory outcomes, offering a significant strategic advantage in the competitive pharmaceutical market.

Market Presence and Competitive Position

Operating across the Americas, EMEA, and Asia Pacific, Certara has cemented its role as a key contributor in the drug development sector. The company’s clientele includes major global biopharmaceutical companies, leading academic institutions, and influential regulatory bodies. Its technology-driven approach to accelerating drug development positions it uniquely within the competitive landscape, providing a robust alternative to traditional clinical trial methodologies and reinforcing its authority in the realm of biosimulation and regulatory strategy services.

Integrated Solutions and Client Benefits

One of the signature aspects of Certara is its integrated platform approach. Products like Certara Cloud offer a centralized portal for accessing multiple software solutions, thus streamlining workflows for users managing diverse aspects of drug development. This integration not only enhances operational efficiency but also provides a scalable and interoperable environment where feedback from users is continually incorporated into the evolution of the company's software suite. By addressing complex drug development challenges with precise and reliable modeling and simulation tools, Certara ensures that scientists and regulators can derive actionable insights more rapidly.

Scientific Expertise and Industry Application

Certara leverages its scientific expertise to address inherent challenges in drug development. The company’s simulation solutions facilitate more informed decision making, improving both the efficiency and safety of clinical trials. Its scientifically advanced models enable the transformation of raw data into strategic insights, thereby streamlining the path from research to patient care. This expertise is critical in an industry where optimizing therapeutic outcomes and meeting regulatory demands are of utmost importance.

Conclusion

In summary, Certara, Inc. stands as a sophisticated confluence of technology, scientific expertise, and regulatory insight. Its comprehensive suite of modeling, simulation, and consulting services provides a concrete foundation for revolutionizing the drug development process. By consistently delivering precise, integrated solutions and employing advanced simulation techniques, Certara plays an instrumental role in bridging the gap between innovative research and the swift, safe delivery of new medicines to patients.

Rhea-AI Summary

Certara, a leader in biosimulation, has appointed Rosemary Crane to its Board of Directors, effective July 21, 2022. This addition increases the board to eleven members. CEO William F. Feehery expressed enthusiasm about Crane's experience in executive leadership and commercialization, which is expected to significantly benefit the company’s growth in the biopharmaceutical sector. Crane brings over 35 years of industry experience, having held leadership positions at several major pharmaceutical companies, including a successful IPO at Epocrates.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.47%
Tags
management
-
Rhea-AI Summary

Certara, a leader in biosimulation, has appointed Eran Broshy to its Board of Directors, effective July 11, 2022, expanding the board to ten members. Broshy brings over 35 years of experience in healthcare, previously serving as CEO and chairman of inVentiv Health, now part of Syneos Health. His expertise in high-growth healthcare businesses is expected to enhance Certara's strategic direction in drug development. Certara's biosimulation software is used by over 2,000 clients globally, aiming to improve patient outcomes.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.85%
Tags
management
-
Rhea-AI Summary

Certara, Inc. (Nasdaq: CERT) will release its Q2 2022 financial results on August 9, 2022, after market close. A conference call with management is scheduled for 5:00 p.m. ET to discuss these results. Interested investors must register online. An archived webcast will be available on the Certara website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.98%
Tags
conferences earnings
Rhea-AI Summary

Certara has launched the Simcyp Discovery Simulator, designed for small molecule drug discovery and translational research. This advanced software enhances early-stage development decisions using physiologically-based pharmacokinetic (PBPK) modeling, aimed at reducing the high failure rate of preclinical drugs. The simulator includes PBPK models for various species and supports early formulation simulations and drug-drug interaction predictions. Certara's commitment to improving drug development processes is underscored by their technological advancements.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.13%
Tags
none
-
Rhea-AI Summary

Certara announces enhancements to its biosimulation tools, including new versions of its Immunogenicity (IG), Immuno-oncology (IO), and Vaccine Simulators. These innovations aim to improve drug development predictability across various therapeutic areas. Key advancements in the IG Simulator (Version 5.0) allow for more comprehensive evaluation of biologics, while the IO Simulator (Version 4.0) facilitates optimal cancer therapy combinations. Additionally, the Vaccine Simulator addresses dosing strategies for diverse patient populations, contributing to the development of next-generation mRNA vaccines.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.28%
Tags
none
-
Rhea-AI Summary

Certara, Inc. (Nasdaq: CERT) reported its Q1 2022 financial results, showcasing a 22% revenue growth to $81.6 million compared to Q1 2021. Net income rose to $2.2 million, reflecting a 110% increase. Adjusted EBITDA was $27.7 million, up 16% year-over-year. The company anticipates FY 2022 revenue guidance between $350 - $360 million and adjusted diluted EPS of $0.48 - $0.53. CEO William F. Feehery emphasized the strong demand for their technology-driven services despite some COVID-related delays.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.46%
Tags
Rhea-AI Summary

Certara, Inc. (Nasdaq: CERT), a leader in biosimulation, announced participation in several upcoming investor conferences. Key events include the Bank of America 2022 Healthcare Conference on May 10, Citi’s Biopharma Virtual Co-Panel Day on May 18, Jefferies Healthcare Conference from June 8-10, and William Blair’s Annual Growth Stock Conference on June 9. Live webcasts will be available on Certara's investor relations website, with replays accessible for 90 days. Certara specializes in accelerating drug discovery using proprietary biosimulation software.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.69%
Tags
conferences
-
Rhea-AI Summary

Certara, Inc. (Nasdaq: CERT) will announce its financial results for Q1 2022 on May 5, 2022, after market close. A conference call to discuss these results will take place at 5:00 p.m. ET. Interested investors can participate by calling specific numbers for domestic and international audiences. Certara utilizes proprietary biosimulation software to enhance drug discovery and development, serving over 2,000 clients worldwide.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.43%
Tags
conferences earnings
-
Rhea-AI Summary

Certara, Inc. (Nasdaq: CERT) reported Q4 2021 revenue of $75.3 million, a 17% increase from Q4 2020. Excluding Pinnacle 21, revenue grew 7%. The net loss narrowed to $9.7 million from $54.5 million year-over-year, while adjusted EBITDA rose 27% to $28.2 million. For 2021, total revenue reached $286.1 million, up 17% year-over-year. However, 2022 revenue guidance was revised down to $350-$360 million. The company is confident in its mid-teens growth target despite challenges from the Omicron variant.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11.07%
Tags
Rhea-AI Summary

Certara announces FDA licensing of its Immunogenicity (IG) Simulator, enhancing drug development capabilities. The simulator predicts immune responses in protein therapeutics, crucial for clinical and regulatory decisions. With over five years of rigorous development, Certara aims to address immunogenicity risks, which can significantly impact drug projects. This technology is validated through 20 clinical studies, facilitating virtual patient trials. Certara serves over 2,000 clients globally, underscoring its role as a leader in biosimulation.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.41%
Tags
none

FAQ

What is the current stock price of Certara (CERT)?

The current stock price of Certara (CERT) is $10.23 as of April 2, 2025.

What is the market cap of Certara (CERT)?

The market cap of Certara (CERT) is approximately 1.6B.

What is the core business of Certara, Inc.?

Certara specializes in providing biosimulation software, modeling solutions, and consulting services to optimize drug development and regulatory processes. Its solutions help reduce clinical trial times and improve patient safety.

How does Certara support drug development?

Certara combines advanced simulation technologies like QSP and PBPK with regulatory consulting, enabling clients to better predict drug behavior and streamline clinical trial design. This integrated approach enhances decision-making throughout the development process.

What technology platforms are provided by Certara?

Certara offers a suite of scientific software solutions including modeling and simulation platforms and integrated solutions such as Certara Cloud. These are designed to provide a cohesive environment for managing diverse aspects of drug development.

Who are the primary clients of Certara?

Certara serves a wide range of clients including global biopharmaceutical companies, academic institutions, and regulatory agencies. These organizations rely on its advanced software solutions and consulting expertise to enhance their drug development pipelines.

How does Certara differentiate itself in the market?

Certara differentiates itself through a unique combination of sophisticated biosimulation technology and deep regulatory expertise. Its integrated platforms and scientifically robust models offer enhanced workflow efficiency and improved regulatory outcomes.

What benefits do clients gain from using Certara's platforms?

Clients benefit from streamlined drug development processes, reduced trial durations, and increased regulatory approval probabilities. The advanced simulation tools provide accurate insights that facilitate informed decision-making across the lifecycle of pharmaceutical development.
Certara, Inc.

Nasdaq:CERT

CERT Rankings

CERT Stock Data

1.58B
120.87M
2.27%
96.57%
3.34%
Health Information Services
Services-prepackaged Software
Link
United States
RADNOR